Trial reportAnnals of internal medicine2010
The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.
Trial report in Annals of internal medicine, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 203 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
Targeting Inflammation Using Salsalate in CardioVascular Disease (TINSAL-CVD)
Targeting Inflammation in Type 2 Diabetes: Clinical Trial Using Salsalate
Targeting Inflammation to Treat Cardiovascular Aging in Humans (TIVA Study)
Using Salsalate to Target Adipocyte Macrophage Infiltration and Reverse Metabolic Disease Risk in Obese Hispanic Young Adults
Who cites it
203 citing papers in PubMed, 6 syntheses or guidelines pooled it, 385 citations in OpenAlex.
- Twenty years of participation of racialised groups in type 2 diabetes randomised clinical trials: a meta-epidemiological review.Diabetologia · 2024Pooled it
- Effects of anti-inflammatory therapies on glycemic control in type 2 diabetes mellitus.Frontiers in immunology · 2023Pooled it
- Type 2 Diabetes: How Much of an Autoimmune Disease?Frontiers in endocrinology · 2019Pooled it
- The effect of periodontal treatment on hemoglobin a1c levels of diabetic patients: a systematic review and meta-analysis.PloS one · 2014Pooled it
- Evidence that periodontal treatment improves diabetes outcomes: a systematic review and meta-analysis.Journal of periodontology · 2013Pooled it
- A meta-analysis of salicylates for type 2 diabetes mellitus.Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban · 2013Pooled it
- A nitroalkene derivative of salicylate, SANA, induces creatine-dependent thermogenesis and promotes weight loss.Nature metabolism · 2025Trial
- Salsalate Improves Postprandial Glycemic and Some Lipid Responses in Persons With Tetraplegia: A Randomized Clinical Pilot Trial With Crossover Design.Topics in spinal cord injury rehabilitation · 2023Trial
- Application value of combination therapy of periodontal curettage and root planing on moderate-to-severe chronic periodontitis in patients with type 2 diabetes.Head & face medicine · 2021Trial
- Acute effects of active breaks during prolonged sitting on subcutaneous adipose tissue gene expression: an ancillary analysis of a randomised controlled trial.Scientific reports · 2019Trial
- Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.Cardiovascular diabetology · 2017 · on this mapTrial
- A Novel NF-κB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying Treatment for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects.Journal of clinical pharmacology · 2017Trial
- Effects of the anti-inflammatory drug salsalate on bone turnover in type 2 diabetes mellitus.Endocrine · 2015Trial
- Salsalate treatment improves glycemia without altering adipose tissue in nondiabetic obese hispanics.Obesity (Silver Spring, Md.) · 2015Trial
- The impact of salsalate treatment on serum levels of advanced glycation end products in type 2 diabetes.Diabetes care · 2014Trial
- The effect of salsalate therapy on endothelial function in a broad range of subjects.Journal of the American Heart Association · 2014Trial
- Targeting inflammation using salsalate in patients with type 2 diabetes: effects on flow-mediated dilation (TINSAL-FMD).Diabetes care · 2013Trial
- Design features of the Diabetes and Periodontal Therapy Trial (DPTT): a multicenter randomized single-masked clinical trial testing the effect of nonsurgical periodontal therapy on glycosylated hemoglobin (HbA1c) levels in subjects with type 2 diabetes and chronic periodontitis.Contemporary clinical trials · 2013Trial
- Trial
- Salicylate (salsalate) in patients with type 2 diabetes: a randomized trial.Annals of internal medicine · 2013Trial
143 more citing papers are in PubMed but not listed here.
Corrections and comments
- SummaryForPatientsIn
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
backgroundSalsalate, a nonacetylated prodrug of salicylate, has been shown to decrease blood glucose concentration in small studies.
objectiveTo compare the efficacy and safety of salsalate at different doses in patients with type 2 diabetes.
designParallel randomized trial with computer-generated randomization and centralized allocation. Patients and investigators, including those assessing outcomes and performing analyses, were masked to group assignment. (ClinicalTrials.gov registration number: NCT00392678)
setting3 private practices and 14 universities in the United States. PATIENTS: Persons aged 18 to 75 years with fasting plasma glucose concentrations of 12.5 mmol/L or less (< or = 225 mg/dL) and hemoglobin A1c (HbA1c) levels of 7.0% to 9.5% treated by diet, exercise, and oral medication at stable doses for at least 8 weeks.
interventionAfter a 4-week, single-masked run-in period, patients were randomly assigned to receive placebo or salsalate in dosages of 3.0, 3.5, or 4.0 g/d for 14 weeks (27 patients each) in addition to their current therapy. MEASUREMENTS: Change in HbA1c was the primary outcome. Adverse effects and changes in measures of coronary risk and renal function were secondary outcomes.
resultsHigher proportions of patients in the 3 salsalate treatment groups experienced decreases in HbA1c levels of 0.5% or more from baseline (P = 0.009). Mean HbA1c changes were -0.36% (P = 0.02) at 3.0 g/d, -0.34% (P = 0.02) at 3.5 g/d, and -0.49% (P = 0.001) at 4.0 g/d compared with placebo. Other markers of glycemic control also improved in the 3 salsalate groups, as did circulating triglyceride and adiponectin concentrations. Mild hypoglycemia was more common with salsalate; documented events occurred only in patients taking sulfonylureas. Urine albumin concentrations increased in all salsalate groups compared with placebo. The drug was otherwise well tolerated. LIMITATION: The number of patients studied and the trial duration were insufficient to warrant recommending the use of salsalate for type 2 diabetes at this time.
conclusionSalsalate lowers HbA1c levels and improves other markers of glycemic control in patients with type 2 diabetes and may therefore provide a new avenue for treatment. Renal and cardiac safety of the drug require further evaluation. PRIMARY FUNDING SOURCE: National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.